kabutan

SAPPORO CLINICAL LABORATORY INC., First Half Ordinary Profit Revised Upward to an Unexpected 16% Increase

Fri Nov 1, 2024 3:30 pm JST Revision

9776 SAPPORO CLINICAL LABORATORY INC. 【J-GAAP】

Guidance Update Report

SAPPORO CLINICAL LABORATORY INC. <9776> [TSE-S] announced a performance revision after the market closed on November 1st (15:30). The consolidated ordinary profit for the cumulative second quarter of the fiscal year ending March 2025 (April to September) has been revised upward by 51.8%, from the previous forecast of 226 million yen to 343 million yen (compared to 296 million yen in the same period of the previous year), turning to a 15.9% increase in the consolidated ordinary profit outlook.

Furthermore, the full-year ordinary profit forecast remains unchanged from the estimate of 493 million yen(compared to 514 million yen in the previous period).

Kabutan News

Guidance Update

First Half Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2024 Prev 9,801 221 226 141 45.2 0 May 13, 2024 J-GAAP
Apr - Sep, 2024 New 9,996 337 343 222 71.2 0 Nov 1, 2024 J-GAAP
Revision Rate +2.0% +52.5% +51.8% +57.4% +57.4%

Current Period Guidance

H1 Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2023 9,862 291 296 226 67.9 0 Nov 10, 2023 J-GAAP
Apr - Sep, 2024 Guidance 9,996 337 343 222 71.2 0 Nov 1, 2024 J-GAAP
YoY +1.4% +15.8% +15.9% -1.8% +4.7%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2023 20,127 1,008 1,159 568 170.5 23 May 12, 2023 J-GAAP
Mar, 2024 19,682 534 514 380 114.1 23 May 13, 2024 J-GAAP
Mar, 2025 Guidance 19,799 500 493 320 102.6 23 May 13, 2024 J-GAAP
YoY +0.6% -6.4% -4.1% -15.8% -10.1%

Related Articles